A potentially life-saving experimental coronavirus drug is nearing the end of its test phase before going to market. A World Health Organization (WHO) panel said in January that remdesivir was is the most promising drug therapy currently under trial.
Now California biotech company Gilead Sciences is on the verge of announcing breakthrough findings after completing trial phases of the anti-viral drug on monkeys and humans.
Doctors in the US have also treated very ill patients with the drug under the Food and Drug Administration’s compassionate use policy.
Human patients who have already entered the study did so for up to 12 days from the onset of Covid-19 symptoms. They were treated with daily IV infusions of remdesivir or a placebo for